6 completed, 2 recruiting. 5 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Recruiting 1 |
| Phase 3 | 3 | Completed 2, Recruiting 1 |
Follow Lasofoxifene: new trials by email Literature Review of Lasofoxifene trials Research Report on Lasofoxifene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib - Metastatic Breast Cancer | Phase 3 | Recruiting | LeonaBio | 600 | 2023-10-31 | 2026-06-22 |
| Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Lasofoxifene and abemaciclib (VERZENIO (R)). - Metastatic Breast Cancer | Phase 2 | Completed | Sermonix Pharmaceuticals Inc. | 29 | 2020-09-29 | 2025-02-13 |
| Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Lasofoxifene, Fulvestrant - Locally Advanced or Metastatic Breast Cancer | Phase 2 | Completed | Sermonix Pharmaceuticals Inc. | 100 | 2019-09-20 | 2026-01-28 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 5000 | 2010-03-01 | 2026-05-06 |
| The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation Lasofoxifene, Placebo - Bone Loss | Phase 2 | Completed | Ligand Pharmaceuticals | 51 | 2004-09-01 | 2011-08-10 |
| Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation lasofoxifene, Placebo, Lasofoxifene - Osteoporosis | Phase 2 | Completed | Ligand Pharmaceuticals | 497 | 2004-06-01 | 2011-08-10 |
| Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss lasofoxifene, raloxifene, Placebo - Osteoporosis | Phase 3 | Completed | Ligand Pharmaceuticals | 540 | 2003-05-01 | 2011-08-12 |
| Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL) lasofoxifene, placebo - Osteoporosis | Phase 3 | Completed | Ligand Pharmaceuticals | 8556 | 2001-11-01 | 2011-08-15 |
Breast Neoplasms (4) · Osteoporosis (4) · Bone Diseases, Metabolic (1) · Hemangiosarcoma (1) · Neoplasms (1) · Pathologic Complete Response (1) · Triple Negative Breast Neoplasms (1)
Ligand Pharmaceuticals (4) · Sermonix Pharmaceuticals Inc. (2) · LeonaBio (1) · QuantumLeap Healthcare Collaborative (1)
United States (6) · Canada (3) · South Korea (3) · United Kingdom (3) · Australia (2) · Belgium (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Japan (2) · Poland (2) · Romania (2) · Spain (2) · Taiwan (2)
Laura Esserman, MD, MBA (1) · Paul V. Plourde, MD (1)
PMID 20181970, PMID 20937977, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 28851423, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37352479, PMID 37505107, PMID 38072513, PMID 38072514, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40222048, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224